Mental health care is fraught with treatment-resistant conditions and ineffective or side-effect-ridden therapies.1 Psychedelic therapy, once relegated to the fringes of medical
Two of the biggest advances in healthcare in the last decade have been the gradual de-stigmatisation of mental health and the increased interest in researching the causes and treatments of
UK-based Small Pharma has launched on the Toronto's TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-Dimethyltryptamine (DMT) to tre